U.S. and Canada Sees More Than $7 Billion in Pharma-Bio Industry Project Starts in First Quarter, an Industrial Info Market Brief

The U.S. and Canadian Pharma-Bio Industry has expanded and retooled manufacturing and laboratory facilities. This expanded capacity has expedited the output of personal protective equipment (PPE), diagnostic reagents, active pharmaceutical ingredients (APIs), medical testing devices, and, most importantly, the discovery of COVID-19 vaccines and therapeutics.